To describe a step-by-step guide for using the first transperineal targeted prostate biopsy platform available in the United States.
A total of 32 men with elevated prostate specific antigen (PSA) diagnosed with a region of interest (ROI) on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The procedure was accomplished transperineal accompanied by a stepper, combined with advanced mpMRI/TRUS fusion software to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer was assessed as well as rate of complications.
The median age was 68.0 years and median PSA was 8.0 ng/mL. Two (6%) patients were active surveillance candidates and 16 (50%) had a prior negative prostate biopsy. The detection rate for overall and clinically significant prostate cancer (csPCa) was 81% and 59%, respectively. Two (100%) candidates for active surveillance and 8 (50%) patients with a prior negative prostate biopsy had csPCa confirmed on targeted biopsy. There were no perioperative complications.
These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the United States as an alternative diagnostic method for prostate cancer. This article is protected by copyright. All rights reserved.
BJU international. 2018 Mar 22 [Epub ahead of print]
Christopher D Kosarek, Ali M Mahmoud, Eduardo J Eyzaguirre, Yong Shan, Eric M Walser, Gary L Horn, Stephen B Williams
Department of Surgery, Division of Urology, The University of Texas, Medical Branch at Galveston., Department of Pathology, The University of Texas, Medical Branch at Galveston., Department of Radiology, The University of Texas, Medical Branch at Galveston.